Integrated BioPharma (INBP) director awarded 50,000 stock options at $0.19 strike
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
INTEGRATED BIOPHARMA INC director Eric J. Friedman received a grant of stock options for 50,000 shares of Common Stock. These options have an exercise price of $0.1900 per share and expire on June 24, 2036. The grant is compensation-related rather than an open‑market purchase.
The options vest and become exercisable in four equal installments of 12,500 options each on September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, aligning vesting with future service periods.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Friedman Eric J
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 50,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 50 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 50,000 options
Exercise price: $0.1900 per share
Expiration date: June 24, 2036
+4 more
7 metrics
Option grant size
50,000 options
Stock Option (Right to Buy) granted to director
Exercise price
$0.1900 per share
Strike price for underlying Common Stock
Expiration date
June 24, 2036
Option term end date
First vesting tranche
12,500 options
Vesting on September 30, 2026
Second vesting tranche
12,500 options
Vesting on December 31, 2026
Third vesting tranche
12,500 options
Vesting on March 31, 2027
Fourth vesting tranche
12,500 options
Vesting on June 30, 2027
Key Terms
Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, vest and become exercisable, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
exercise price financial
"conversion_or_exercise_price: "0.1900""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest and become exercisable financial
"The stock options vest and become exercisable in four equal installments"
Common Stock financial
"underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
What did Eric J. Friedman do in this INBP Form 4 filing?
Director Eric J. Friedman received a grant of 50,000 stock options for Integrated BioPharma Inc. These options are a compensation award, not an open-market share purchase or sale, and give him the right to buy common stock at a fixed exercise price.
What are the key terms of Eric J. Friedman’s new INBP stock options?
The grant covers 50,000 stock options on Integrated BioPharma common stock with a $0.1900 exercise price per share. The options expire on June 24, 2036, providing a long-term opportunity to acquire shares if the stock trades above the exercise price.
How do the INBP stock options granted to Eric J. Friedman vest?
The 50,000 stock options vest in four equal installments of 12,500 each. Vesting dates are September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, meaning Friedman gains exercisability gradually over this period.
What does the expiration date mean for Eric J. Friedman’s INBP options?
The options expire on June 24, 2036, after which any unexercised options become worthless. Until then, once vested, Friedman may choose to exercise them at $0.1900 per share if market conditions make exercising economically attractive compared with the current stock price.